[ Vivace Therapeutics raises $25M in Series B funding ]

Vivace Therapeutics has raised $25 million in Series B funding.

Founded in 2014, Vivace Therapeutics  is an oncology-based pharmaceutical company that discovers, develops and provides therapeutics for cancer. The company says its drug discovery and development efforts will initially focus on inhibitors of the Hippo-YAP signaling pathway.

Vivace is also developing novel therapeutic antibodies — called BINspecific™ antibodies (bi-specific irreversible cell-type specific antibodies)— that bind in a nearly irreversible and cell-type specific manner to target cells.

Funding  Series B
Founded  2014
Country  USA
City  San Mateo, California
Founder / CEO  Sofie Qiao
Deal Size  $25M
Investors  WuXi Healthcare Ventures
 Mission Bay Capital
 Canaan Partners
 Sequoia Capital
 Cenova Ventures
Previous Investors  Canaan Partners
 WuXi Healthcare Ventures